SASB

Home > SASB > Drug supply chain integrity > HC-DR-250a.2

Data pertaining to 2023

Overview Energy management in retail Management of controlled substances Drug supply chain integrity Activity metrics Patient health outcomes Data security and privacy

Drug supply chain integrity

GRI HC-DR-250a.2

Number of drug recalls issued, Total units recalled, Percentage for private-label products

In 2023, we recalled 36 products, none of which from Private Labels. These cases consider both voluntary recalls by manufacturers and those required by Anvisa. We do not have control over the number of units collected.